Compare BEN & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEN | HOLX |
|---|---|---|
| Founded | 1947 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Electronics |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 16.6B |
| IPO Year | N/A | 1990 |
| Metric | BEN | HOLX |
|---|---|---|
| Price | $23.40 | $74.98 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 11 | 15 |
| Target Price | $23.05 | ★ $79.64 |
| AVG Volume (30 Days) | ★ 4.3M | 3.0M |
| Earning Date | 11-07-2025 | 11-03-2025 |
| Dividend Yield | ★ 5.47% | N/A |
| EPS Growth | ★ 7.28 | N/A |
| EPS | 0.91 | ★ 2.49 |
| Revenue | ★ $8,770,700,000.00 | $4,100,500,000.00 |
| Revenue This Year | N/A | $6.69 |
| Revenue Next Year | $5.60 | $5.74 |
| P/E Ratio | ★ $25.71 | $30.11 |
| Revenue Growth | ★ 3.45 | 1.74 |
| 52 Week Low | $16.25 | $51.90 |
| 52 Week High | $26.08 | $80.31 |
| Indicator | BEN | HOLX |
|---|---|---|
| Relative Strength Index (RSI) | 60.98 | 67.93 |
| Support Level | $22.34 | $74.55 |
| Resistance Level | $23.54 | $75.12 |
| Average True Range (ATR) | 0.46 | 0.28 |
| MACD | 0.19 | -0.14 |
| Stochastic Oscillator | 94.44 | 78.92 |
Franklin Resources provides investment services for individual and institutional investors. At the end of July 2025, Franklin had $1.617 trillion in managed assets, composed primarily of equity (41%), fixed-income (27%), multi-asset/balanced (11%) funds, alternatives (16%) and money market funds (5%). Distribution tends to be weighted between retail investors (56% of AUM) and institutional accounts (41%), with high-net-worth clients accounting for the remainder. Franklin is one of the more global of the US-based asset managers we cover, with 31% of its assets under management invested in global/international strategies and just as much sourced from clients domiciled outside the United States.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.